Allergenic Product Reclassification Will Be Discussed At April 7 Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
The committee will assess whether Class IIIA products should remain licensed or be pulled from the market. An update on FDA's "critical path" drug development initiative is also on the agenda.
You may also be interested in...
Allergenic Product New Data To Be Considered By Cmte. In Reclassification Review
Data generated since 1983 reclassification panel report will aid FDA’s Allergenic Products Advisory Committee in determining agency’s position on categories for allergenic products on April 7. Reclassification panel’s recommendations in 1983 to classify most allergenic products as Category I were never implemented by FDA.
Allergenic Product New Data To Be Considered By Cmte. In Reclassification Review
Data generated since 1983 reclassification panel report will aid FDA’s Allergenic Products Advisory Committee in determining agency’s position on categories for allergenic products on April 7. Reclassification panel’s recommendations in 1983 to classify most allergenic products as Category I were never implemented by FDA.
Senate Drug Safety Hearings Will Take Broad View Of FDA Process
The Senate Health Committee is planning a series of hearings on drug safety issues in March on topics including FDA’s drug approval process and the delayed “Critical Path” drug development initiative. It is premature to predict how drug safety controversies will impact FDA post-marketing authority, House and Senate staffers say.